Related Experiment Video
Updated: Sep 13, 2025
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Identifying Cellular Stress-Related mRNA Changes Induced by Novel Xanthone Derivatives in Ovarian Cancer Cells In
Jakub Rech1, Dorota Żelaszczyk2, Henryk Marona2
1Department of Biotechnology and Genetic Engineering, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland.
Abstract:
Background: Ovarian cancer is a major challenge in oncology due to high mortality rates, especially in advanced stages, despite current therapeutic approaches relying on chemotherapy and surgery. The search for novel therapeutic strategies is driven by the need for more effective treatments. This study focuses on novel xanthone derivatives modified with a morpholine ring, aiming to improve anticancer efficacy. Methods: In silico studies were conducted using ProTox III and SwissADME databases to assess the toxicity and ADME properties of the synthesized compounds. Molecular changes in cellular stress-related genes were investigated through qPCR in two ovarian cancer cell lines (TOV-21G and SKOV-3) following treatment with the compounds. Results: In silico analyses predicted high gastrointestinal absorption and blood-brain barrier permeability for the derivatives. Compounds exhibited varying toxicity and metabolic profiles. qPCR revealed significant alterations in genes related to antioxidant enzymes, molecular chaperones, and xenobiotic metabolism, indicating potential mechanisms of action and cellular responses to the compounds. Conclusions: The study demonstrates the potential of novel xanthone derivatives as promising candidates for ovarian cancer therapy, with implications for enhancing therapeutic efficacy and addressing drug resistance. Further research is warranted to elucidate the precise mechanisms underlying the observed effects and to develop tailored treatment strategies leveraging these agents.
Insights
Novel xanthone derivatives show promise for ovarian cancer treatment. These compounds demonstrated potential anticancer effects and altered cellular stress responses in preclinical studies.
Area of Science:
- Oncology
- Medicinal Chemistry
Background:
- Ovarian cancer presents a significant challenge in oncology with high mortality rates, particularly in advanced stages.
- Current treatments like chemotherapy and surgery have limitations, necessitating the development of novel therapeutic strategies.
- This research explores novel xanthone derivatives incorporating a morpholine ring to enhance anticancer efficacy.
Purpose of the Study:
- To evaluate the potential of novel xanthone derivatives as therapeutic agents for ovarian cancer.
- To assess the in silico toxicity and ADME properties of these compounds.
- To investigate the impact of these derivatives on cellular stress-related genes in ovarian cancer cell lines.
Main Methods:
- In silico analysis using ProTox III and SwissADME for toxicity and ADME profiling.
- Quantitative PCR (qPCR) to analyze gene expression changes in ovarian cancer cell lines (TOV-21G, SKOV-3).
- Treatment of cell lines with synthesized xanthone derivatives to observe molecular responses.
Main Results:
- In silico studies predicted favorable gastrointestinal absorption and blood-brain barrier permeability for the derivatives.
- Compounds displayed varied toxicity and metabolic profiles.
- qPCR analysis indicated significant modulation of genes involved in antioxidant defense, molecular chaperoning, and xenobiotic metabolism.
Conclusions:
- Novel xanthone derivatives exhibit potential as candidates for ovarian cancer therapy.
- These compounds may offer enhanced therapeutic efficacy and strategies to overcome drug resistance.
- Further investigation is required to fully understand the mechanisms of action and optimize treatment strategies.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024